[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: Volume 19, Issue 2 (4-2021) ::
Int J Radiat Res 2021, 19(2): 243-249 Back to browse issues page
Moderate hypofractionated volumetric modulated Arc therapy with daily image guidance for patients with localized prostate cancer
H.J. Kim , J.S. Lee , W.C. Kim
Department of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, Korea , cancerovercome@gmail.com
Abstract:   (2060 Views)
Background: Technical advances have allowed the delivery of a higher dose to the tumor volumes, while reducing the dose to nearby organs at risk. Laboratory and clinical evidence suggest that hypofractionation might raise the therapeutic effect. We report our outcomes of moderately hypofractionated schedules with volumetric modulated arc radiotherapy (VMAT) on biochemical failure (BCF) free survival and toxicities in patients with localized prostate cancer. Materials and Methods: Between 2013 and 2017, 58 patients were treated using the VMAT technique with daily image guided radiotherapy (IGRT). 3 (5.2%), 32 (55.2%), and 23 (39.7%) of patients had low, intermediate, or high risk disease, respectively. A prescription dose of 70 Gy in 2.5 Gy daily for 28 fractions was used. BCF-free survival was evaluated using 2005 Phoenix criteria and estimated using the Kaplan–Meier method. Radiotherapy-related toxicity was scored according to the Common Terminology Criteria for Adverse Events 4.0 criteria. Results: The median follow-up was 37.3 months (range 18.8-82.1). Overall 4 year BCF-free survival were 94.0%. For low-intermediate and high risk patients, the 4 year BCF-free survival were 100% and 83.3%, respectively (p=0.027). Pretreatment prostate-specific antigen (p=0.016) and Gleason score (p=0.007) were significant predictors of BCF-fee survival. The incidence of late grade 2 gastrointestinal and genitourinary toxicity was 8.6% and 13.8%, respectively. No grade 3 or greater toxicities were observed. Conclusions: Outcoms after moderately hypofractionated VMAT-IGRT were encouraging. Moderate hypofractionation was effective and safe for the treatment of localized prostate cancer.
Keywords: Prostate cancer, Moderate hypofractionation, Volumetric modulated Arc radiotherapy, PSA, Image guidance radiotherapy.
Full-Text [PDF 1526 kb]   (748 Downloads)    
Type of Study: Original Research | Subject: Medical Physics
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kim H, Lee J, Kim W. Moderate hypofractionated volumetric modulated Arc therapy with daily image guidance for patients with localized prostate cancer. Int J Radiat Res 2021; 19 (2) :243-249
URL: http://ijrr.com/article-1-3638-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 2 (4-2021) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.06 seconds with 50 queries by YEKTAWEB 4645